Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Size, Share, Industry, and Outlook (2024-2031)

Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market is segmented By Drug Class (Calcium Channel Blockers, Nifedipine, Amlodipine, Others, Immunosuppressive Agents, Mycophenolate Mofetil, Methotrexate, Cyclophosphamide, Rituximab, Tocilizumab, Others, Pulmonary Vasodilators, Pentoxifylline, Nitroglycerin, Others, Proton Pump Inhibitors, Phosphodiesterase Inhibitors (Sildenafil), Corticosteroids, Others), By Route Of Administration (Oral, Subcutaneous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market is expected to reach at a high CAGR during the forecast period 2024-2031.

Diffuse cutaneous systemic sclerosis (DcSSc) is a subtype of systemic scleroderma (systemic sclerosis) characterized by skin hardening (fibrosis) and problems in many organs of the body. The disease can occur at any age but mainly affects people between 40 and 50 years of age. Dry mouth and dental involvement can occur. Joint pain (arthralgias), muscular pain, weakness, cramps, and destruction of the tips of the fingers or toes (acroosteolysis) are frequent. Severe problems involving the lung (fibrosis or pulmonary hypertension) and kidney problems may also occur.

Moreover, the exact cause of the condition is unknown. There is currently no cure for diffuse cutaneous systemic sclerosis. Treatment depends on the symptoms but may include medication and surgery. Raynaud's phenomenon can be treated with calcium channel blockers. Proton pump inhibitors are given for gastric reflux. Surgical resection of severe calcinosis may be required. Low doses of corticosteroids with immunosuppressive agents are needed in cases with recent severe cutaneous involvement or in progressive lung fibrosis. Pulmonary vasodilators are given in case of pulmonary arterial hypertension.

Market Summary

To Know More Insights - Download Sample

Market Dynamics

Increasing demand for innovative drugs 

The increasing demand for innovative drugs for the treatment of diffuse cutaneous systemic sclerosis is expected to drive the market over the forecast period. The existing treatments for DcSSc are not fully effective or have significant side effects, there is a high demand for innovative drugs that can address these unmet medical needs. The innovative drugs aim to address the unmet needs associated with the management of diffuse cutaneous systemic sclerosis by providing alternative or complementary treatment options for better disease management. 

Moreover, many clinical trials are going on for the development of innovative drugs that show better results in diffuse cutaneous systemic sclerosis treatment. Positive results from clinical trials evaluating the efficacy and safety of new drugs can boost demand. If a novel drug demonstrates significant improvements in treating DcSSc in clinical studies, it is likely to increase the adoption.

For instance, on February 21, 2023, ChemomAb Ltd., a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, released the U.S. Food and Drug Administration (FDA) clearance of the company's Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with diffuse cutaneous systemic sclerosis.

Further, the increasing prevalence of the diffuse cutaneous systemic sclerosis, rising FDA approvals, increasing clinical trials, increasing awareness about the drug's availability and advancements in developing novel drugs are expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the high doses of drugs,  the high cost of some treatment drugs, lack of appropriate treatment and the availability of alternative treatment options are expected to hamper the market. 

Market Segment Analysis

The global diffuse cutaneous systemic sclerosis(DcSSc) drugs market is segmented based on drug class, route of administration, distribution channel and region.

The immunosuppressives segment accounted for approximately 39.3% of the diffuse cutaneous systemic sclerosis(DcSSc) drugs market share

The immunosuppressive agents are expected to hold the largest market share over the forecast period. Usually, there is no cure for this disease, but immunosuppressives such as mycophenolate mofetil, methotrexate, cyclophosphamide, rituximab, tocilizumab and other immunosuppressives are most commonly used for the treatment of the diffuse cutaneous systemic sclerosis.

Due to the rising prevalence of the diffuse cutaneous systemic sclerosis, the demand for the use of immunosuppressives is continuously increasing. For instance, according to the National Organization for Rare Disorders, approximately one in 10,000 individuals is affected with systemic sclerosis including diffuse cutaneous systemic sclerosis. It is more common in women and most often develops around age 30 to 50.

Further, methotrexate is commonly used in the treatment of autoimmune diseases, including DcSSc. Methotrexate can help reduce inflammation and modify the immune response. Mycophenolate Mofetil immunosuppressant is another option that is used to treat DcSSc. It works by inhibiting the proliferation of immune cells. Rituximab targets specific B cells in the immune system. It may be used in cases of DcSSc where B cells play a significant role. In addition, their wide adoption also increases the demand for immunosuppressives. 

Market Geographical Share

North America accounted for approximately 40.1% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and biotechnology companies. This strong presence of major players actively performs in clinical trials for the development of novel drugs.

For instance, on November 9, 2021, Horizon Therapeutics plc released that the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with diffuse cutaneous systemic sclerosis, a subset of systemic sclerosis (also known as scleroderma).

Furthermore, the region is also very well known for its advanced healthcare infrastructure such as hospitals, specialty clinics and academic and research institutes which provide advanced treatment facilities for diffuse cutaneous systemic sclerosis by using novel and better drugs which results in better patient outcomes. The research and academic institutes always focus on the research activities for the development of the innovative drugs 

Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Companies

The major global players in the diffuse cutaneous systemic sclerosis (DcSSc) drugs market include Lupin Pharmaceuticals, Inc., Bayer AG, Genentech, Inc., Pfizer Inc., Jubilant Cadista Pharmaceuticals Inc., Corbus Pharmaceuticals Holdings, Inc., Horizon Therapeutics plc, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Kadmon Pharmaceuticals, LLC. And among others. 

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global diffuse cutaneous systemic sclerosis (DcSSc) drugs market. The pandemic led to disruptions in clinical trials across various therapeutic areas, including for new DcSSc drugs or those investigating expanded indications may have faced delays temporarily due to the redirected focus towards the COVID-19 pandemic, this results in impacting timelines for drug development and regulatory approvals. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global diffuse cutaneous systemic sclerosis drugs market segmentation based on drug class, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of diffuse cutaneous systemic sclerosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global diffuse cutaneous systemic sclerosis drugs market report would provide approximately 61 tables, 61 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies